# A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.

> **NCT00365131** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 40 (—)

## Conditions studied

- Gaucher Disease Type I
- Cerebroside Lipidosis Syndrome
- Clucocerebrosidase Deficiency Disease
- Glucosylceramide Beta-Glucosidase Deficiency Disease
- Gaucher Disease, Non-Neuronopathic Form

## Interventions

- **DRUG:** Cerezyme (imiglucerase for injection)

## Key facts

- **NCT ID:** NCT00365131
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 40 (—)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365131, "A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00365131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*